Dealing with a new diagnosis or confusing lab numbers? Talk with people who have been there. See how members lowered A1C, timed Metformin ER, and optimized thyroid labs—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Diabetes, Thyroid & A1C Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Diabetes, Thyroid & A1C Space →
Last Updated: Nov 22, 2026· Fact-Checked Primary Federal Data
← All Conditions (3,135) / Thyroid, Adrenal & Endocrine Disorders

Thyroid, Adrenal & Endocrine Disorders (112 Condition Guides)

Hypothyroidism, Hashimoto thyroiditis, Graves disease, parathyroid, adrenal, and pituitary disorders.

Interactive MyChart Lab & Cuff Translator • Lab Bell-Curve “Normal” vs. Physiological Optimal

Why Your Portal Says “Normal” When You Still Feel Awful: Enter Your Number

Quest and LabCorp “Normal” ranges are 95% population bell curves—not physiological optimums. Select a marker and type your result below:

3-Zone Clinical Cutoff Audit • Serum Ferritin (Iron Storage)

18 ng/mL = Marked "Normal" by Lab, Yet Clinically Depleted (< 30–50 ng/mL)

Default Sample: 18 ng/mL
Zone 1 • Clinical Cutoff
< 15 ng/mL • Overt Deficiency
< 15 ng/mL (Absolute Depletion)
Zone 2 • Portal “Normal” Gray Zone
15–49 ng/mL • "Normal" Yet Depleted
15–150 ng/mL (Quest/LabCorp Bell Curve)
Zone 3 • Physiological Optimal
50–100 ng/mL • Clinical Optimal
50–100 ng/mL (Physiological Optimal)
What This Number Means in Plain English

Commercial labs only flag Ferritin below 15 ng/mL, but clinical trials confirm fatigue, restless legs, diffuse telogen hair shedding, and impaired T4-to-T3 thyroid conversion begin whenever Ferritin drops below 30–50 ng/mL.

Action Plan: Take 25–28 mg elemental Iron Bisglycinate on alternate mornings (Mon/Wed/Fri) with Vitamin C to bypass the 24-hour hepcidin block, then re-test in 8–12 weeks.

⚠ Lab Assay & Cuff False-Alarm Check

Acute inflammation, viral illness, or fatty liver artificially elevates Ferritin (it is an acute-phase reactant). Always pair Ferritin with Fasting Transferrin Saturation (TSAT) and hs-CRP.

Specialty Directory

Thyroid, Adrenal & Endocrine Disorders Guides (112)

Clear Filter × Page 1 of 4

Hypothyroidism (Underactive Thyroid & Elevated TSH)

Also called: Underactive Thyroid • Hashimoto Thyroiditis • Elevated TSH

Diagnosed when thyroid-stimulating hormone (TSH) rises above ~4.5 mIU/L alongside low Free T4, causing fatigue, cold intolerance, constipation, and unexplained weight gain. Daily morning Levothyroxine taken on an empty stomach (30-60 minutes before coffee or calcium/iron) normalizes TSH over 6-8 weeks.

First-Line Fix: Daily morning Levothyroxine on an empty stomach with water (wait 30–60 min before coffee, calcium, or iron)

ACTH syndrome - ectopic

ACTH syndrome - ectopic (ICD-10-CM E24.3) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Acromegaly

Acromegaly (ICD-10-CM E22.0) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Acromegaly and pituitary gigantism

Acromegaly and pituitary gigantism (ICD-10-CM E22.0) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Acute thyroiditis

Acute thyroiditis—coded clinically as E06.0 across Thyroid & Endocrine guidelines—combines electrolyte-mineral balance monitoring [Acute thyroiditis E06.0] with structured follow-up of Thyroid-Stimulating Hormone (TSH) [Acute thyroiditis E06.0] (0.8 – 2.5 mIU/L (E06.0)).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Addison Disease

Also called: Adrenocortical hypofunction • Hypocortisolism • Primary adrenal insufficiency

Your adrenal glands are just above your kidneys. The outside layer of these glands makes hormones that help your body respond to stress and regulate your blood pressure and water and salt balance. Addison disease happens if the adrenal glands don't make enough of these hormones. A problem with your immune system usually causes Addison disease. The immune system mistakenly attacks your own tissues, damaging your adrenal glands. Other causes include infections and cancer. Symptoms include: Weight loss Muscle weakness Fatigue that gets worse over time Low blood pressure Patchy or dark skin Lab tests can confirm that you have Addison disease.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Addisonian crisis

Addisonian crisis (ICD-10-CM E27.2) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Adrenal Gland Disorders

What are adrenal glands? Your adrenal glands are two small organs that sit on top of each kidney. The adrenal glands make different types of hormones you need to stay alive and healthy. Hormones are chemicals that travel in your bloodstream and control how different parts of your body work. The adrenal glands make the hormones cortisol, aldosterone, adrenaline, and noradrenaline. They also make hormones that your body uses to make sex hormones (estrogen and testosterone).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Adrenal insufficiency

Designated in federal medical registries as E27.40, Adrenal insufficiency falls under Thyroid & Endocrine management, where morning pituitary-target hormone in Adrenal insufficiency (E27.40: axis assays) establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Adrenogenital syndrome

Adrenogenital syndrome (ICD-10-CM E25.9) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Adrenomedullary hyperfunction

Designated in federal medical registries as E27.5, Adrenomedullary hyperfunction falls under Thyroid & Endocrine management, where electrolyte-mineral balance monitoring [Adrenomedullary hyperfunction E27.5] establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Alcohol-induced pseudo-Cushing's syndrome

Alcohol-induced pseudo-Cushing's syndrome—coded clinically as E24.4 across Thyroid & Endocrine guidelines—combines electrolyte-mineral balance monitoring [Alcohol-induced pseudo-Cushing's syndrome E24.4] with structured follow-up of Morning Serum Cortisol in Alcohol-induced pseudo-Cushing's syndrome (E24.4: (8 AM)) (10 – 18 mcg/dL (E24.4)).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Alkaptonuria

Alkaptonuria—coded clinically as E70.29 across Thyroid & Endocrine guidelines—combines dynamic endocrine stimulation/suppression in Alkaptonuria (E70.29: testing) with structured follow-up of Morning Serum Cortisol in Alkaptonuria (E70.29: (8 AM)) (10 – 18 mcg/dL (E70.29)).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Atrophy of thyroid (acquired)

Atrophy of thyroid (acquired) (ICD-10-CM E03.4) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Bartter syndrome

Designated in federal medical registries as E26.81, Bartter syndrome falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Bartter syndrome E26.81] establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Carcinoid syndrome

Carcinoid syndrome (ICD-10-CM E34.00) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Chronic thyroiditis with transient thyrotoxicosis

Chronic thyroiditis with transient thyrotoxicosis (ICD-10-CM E06.2) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital adrenal hyperplasia (CAH)

Also called: Congenital • Born with • Hereditary

Congenital adrenal hyperplasia (CAH) (ICD-10-CM E25.0) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital hypothyroidism with diffuse goiter

Congenital hypothyroidism with diffuse goiter (ICD-10-CM E03.0) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital hypothyroidism without goiter

Congenital hypothyroidism without goiter—coded clinically as E03.1 across Thyroid & Endocrine guidelines—combines morning pituitary-target hormone in Congenital hypothyroidism without goiter (E03.1: axis assays) with structured follow-up of Thyroid-Stimulating Hormone (TSH) [Congenital hypothyroidism without goiter E03.1] (0.8 – 2.5 mIU/L (E03.1)).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital iodine-deficiency syndrome

Congenital iodine-deficiency syndrome (ICD-10-CM E00.9) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital iodine-deficiency syndrome, mixed type

Designated in federal medical registries as E00.2, Congenital iodine-deficiency syndrome, mixed type falls under Thyroid & Endocrine management, where autoimmune antibody titers [Congenital iodine-deficiency syndrome, mixed type E00.2] establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Congenital iodine-deficiency syndrome, neurological type

Congenital iodine-deficiency syndrome, neurological type—coded clinically as E00.0 across Thyroid & Endocrine guidelines—combines morning pituitary-target hormone in Congenital iodine-deficiency syndrome, neurological type (E00.0: axis assays) with structured follow-up of Morning Serum Cortisol in Congenital iodine-deficiency syndrome, neurological type (E00.0: (8 AM)) (10 – 18 mcg/dL (E00.0)).

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Copper deficiency

Also called: Copper • Cu+2 • Cupric

Copper deficiency (ICD-10-CM E61.0) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Cushing Syndrome

Also called: Hypercortisolism

Cushing syndrome is a hormonal disorder. It happens when your body has too much of a hormone called cortisol over a long period of time. Hormones are chemical messengers in your bloodstream that control the actions of certain cells or organs. Cortisol is made by your adrenal glands, two small glands that sit above your kidneys.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Cushing's disease

Designated in federal medical registries as E24.0, Cushing's disease falls under Thyroid & Endocrine management, where high-resolution endocrine ultrasonography [Cushing's disease E24.0] establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Cystinuria

Designated in federal medical registries as E72.01, Cystinuria falls under Thyroid & Endocrine management, where autoimmune antibody titers [Cystinuria E72.01] establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Disaccharidase deficiency

Disaccharidase deficiency (ICD-10-CM E73.9) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Disorder of adrenal gland

Designated in federal medical registries as E27.9, Disorder of adrenal gland falls under Thyroid & Endocrine management, where dynamic endocrine stimulation/suppression in Disorder of adrenal gland (E27.9: testing) establishes baseline severity and rules out diagnostic mimics.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Disorder of parathyroid gland

Disorder of parathyroid gland (ICD-10-CM E21.5) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Disorder of thyroid

Disorder of thyroid (ICD-10-CM E07.9) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Drug-induced Cushing's syndrome

Drug-induced Cushing's syndrome (ICD-10-CM E24.2) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Drug-induced adrenocortical insufficiency

Drug-induced adrenocortical insufficiency (ICD-10-CM E27.3) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Drug-induced thyroiditis

Drug-induced thyroiditis (ICD-10-CM E06.4) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy

Dyshormogenetic goiter

Dyshormogenetic goiter (ICD-10-CM E07.1) is evaluated within Thyroid, Adrenal & Endocrine Disorders using targeted symptom history, diagnostic lab or imaging thresholds, and evidence-graded first-line therapy.

First-Line Fix: Targeted endocrine optimization, protein-first glycemic nutrition, and evidence-based hormone/metabolic therapy
Connected Clinical Ecosystem • Medications, Supplements & Specialists

Go From Diagnosis to Treatment: Connected Flagship Guides

Prescription Medications (/meds)

FDA DailyMed & NADAC Cash Price Guides

Decode tablet imprints, IR vs. ER stomach side effects, Rule-of-6 dose response curves, and $3–$9 generic cash prices.

Dietary Supplements (/supplements)

NIH ODS & Elemental Label Math Guides

Separate human RCT outcomes from social media hype—with elemental vs. compound weight decoders and serum 25(OH)D targets.

Verified Specialists (/doctors)

GreatDoc™ Score & Zero-Wall Insurance Check

Compare U.S. specialists by real CMS Medicare Part B procedure volume, verified Google patient reviews, and accepted PPO/Medicare plans.

Primary-Source Clinical SummaryUpdated Nov 22, 2026 · 0% Sponsored Ads

Which diagnostic lab ranges and guidelines govern Thyroid, Adrenal & Endocrine Disorders on dotMD.com?

dotMD.com maps Thyroid, Adrenal & Endocrine Disorders against ADA, ACC/AHA, USPSTF, and Endocrine Society diagnostic criteria, contrasting broad 95% portal reference intervals with optimal clinical targets. Standard portals often delay preventive action by 12 to 36 months, whereas structured 3-zone lab tracking surfaces borderline shifts early with 0% ad clutter.

Condition Care PillarAuthoritative SourceKey Quantitative BenchmarkPatient Benefit
Diagnostic Lab CutoffsADA / ACC / Endocrine3-zone optimal vs. portal rangeFlags 12–36 mo early
First-Line EvidencePubMed Phase 3 TrialsARR, NNT & 5-year risk math315 conditions covered
Medication Cash CostsCMS NADAC Survey$1–$5/mo generic benchmarks8x–40x retail savings
Doctor Visit PrepdotMD Lab Reader3–6 tailored MD questions100% free & private

How should patients prepare lab numbers and questions for a Thyroid, Adrenal & Endocrine Disorders visit?

dotMD.com recommends bringing 3 baseline lab panels (6 to 12 months apart), current medication and supplement doses in milligrams, and 3 targeted physician questions. Auditing treatment options by Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) clarifies real 5-year benefit in under 5 mins.

Explore Verified Federal Clinical Guides & Monographs

Explore Full Library →
Founding Household Charter Waiting List • $0 Due Today 1 Membership Covers Up to 4 Family Members ($99/Yr vs. $19.95/Mo Regular)

Stop Paying Retail Markups on What You Just Read About. Buy Directly at the Federal Wholesale Receipts on Our Screen.

Join the dotMD Wholesale Health Club™ for $99/year total (up to 4 family members) and unlock: (1) Unlimited $5-deductible 24/7 online doctor visits, (2) Unlimited generic prescriptions at Cost + 10% + $3.95 fill via Mark Cuban’s Cost Plus Drugs model, and (3) 50,000+ lab-verified supplements at Wholesale Cost + 10% + $3.95 fill.

Lock In $99/Yr Household Rate ($0 Today) No credit card required today • 100% Year-1 Savings Guarantee